Hematopoietic growth factors: ESMO recommendations for the applications.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Oncology

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdp162PMID 19454444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

  2008cited by this paper
• The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.

  2008cited by this paper
• Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults.

  2007cited by this paper
• Canadian supportive care recommendations for the management of neutropenia in patients with cancer

  2007cited by this paper
• Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection

  2007cited by this paper
• Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

  2007cited by this paper
• Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

  2007cited by this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cited by this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cited by this paper
• Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

  2005cited by this paper
• Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group

  2004cited by this paper
• Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

  2004cited by this paper
• Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group

  2004cited by this paper
• Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.

  2003cited by this paper
• A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

  2003cited by this paper
• Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults.

  2003cited by this paper
• Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.

  1999cited by this paper
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

  1994cited by this paper

• Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.

  2026cites this paper
• Curative intent therapy for DLBCL in the elderly

  2024cites this paper
• High D‐index during mobilization predicts poor mobilization of CD34+ cells after anti‐lymphoma salvage chemotherapy

  2021cites this paper
• Membres du groupe de travail

  2020cites this paper
• Pattern of management of febrile neutropenia among breast cancer patients treated with different chemotherapeutic regimens

  2018cites this paper
• Hematological Side Effects

  2017cites this paper
• Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

  2017cites this paper
• Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia.

  2017cites this paper
• Chapter 18 – Total Body Irradiation

  2016cites this paper
• Radiation therapy and neutropenia.

  2015cites this paper
• Management of Acute Radiation Side Effects

  2015cites this paper
• Hematopoietic Growth Factors

  2015cites this paper
• Non-small cell lung cancer in a patient with primary myelodysplastic syndrome

  2014cites this paper
• Model-Based Approach to Early Predict Prolonged High Grade Neutropenia in Carboplatin-Treated Patients and Guide G-CSF Prophylactic Treatment

  2014cites this paper
• Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma

  2013cites this paper
• Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients

  2013cites this paper
• A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

  2013cites this paper
• Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.

  2013cites this paper
• A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

  2013cites this paper
• Are aging biomarkers clinically relevant in oncogeriatrics?

  2013cites this paper
• Modélisation pharmacocinétique/pharmacodynamique par une approche de population de l’effet du G-CSF chez des patients traités avec du carboplatine

  2013cites this paper
• Willingness to communicate in health care – a multi-3 professional approach Cover Story ECOP 2012 Conference Preview

  2013cites this paper
• Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.

  2012cites this paper
• Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

  2012cites this paper
• Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

  2012cites this paper
• Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.

  2012cites this paper
• [Focus on granulocyte colony-stimulating factor-induced pulmonary toxicity].

  2012cites this paper
• Urgences chez le patient atteint de cancer

  2011cites this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cites this paper
• Elucidating the functionality of kinesins: an overview of small molecule inhibitors.

  2011cites this paper
• Éviter et gérer l’urgence fébrile en oncologie

  2011cites this paper
• The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is ‘just right’?

  2011cites this paper
• Urgences hématologiques et oncologiques

  2011cites this paper
• Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment

  2011cites this paper
• Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG‐14

  2011cites this paper
• Supportive therapy in multiple myeloma.

  2011cites this paper
• [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].

  2010cites this paper
• Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.

  2010cites this paper
• Rationale and recommendations for treatment of radiation injury with cytokines.

  2010cites this paper
• Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation

  2010cites this paper
• Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines.

  2010cites this paper
• Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim

  2010cites this paper
• The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

  2010cites this paper
• Supportive Therapie bei multiplem Myelom

  2010cites this paper
• Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

  2010cites this paper
• Clinical and economic benefits of using pegfilgrastim post autologous stem cell transplant

  2010cites this paper
• 15 – Total Body Irradiation

  2010cites this paper
• A CASE OF AORTIC VALVE REPLACEMENT IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND AORTIC VALVE STENOSIS

  2010cites this paper
• Prise en charge des neutropénies fébriles au cours du cancer bronchique

  2010cites this paper
• Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

  2010cites this paper
• Pegfilgrastim en la prevención primaria de la neutropenia severa inducida por quimioterapia

  2010cites this paper
• Neutropénie fébrile chez le patient adulte atteint de tumeur solide : revue de la littérature pour une gestion rationnelle et optimale

  2010cites this paper
• Neutropenic enterocolitis: A continuing medical and surgical challenge

  2010influential citation
• Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

  2010cites this paper
• Pegfilgrastim vs. Filgrastim zur Primärprophylaxe der febrilen Neutropenie bei Brustkrebspatientinnen nach Chemotherapie

  2010cites this paper
• Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study

  2010cites this paper
• [Febrile neutropenia in adult patients with solid tumours: a review of literature toward a rational and optimal management].

  2010cites this paper
• Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

  2009cites this paper
• Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age

  2009cites this paper
• Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

  2009cites this paper
• Manejo general y extrahospitalario del paciente en tratamiento con quimioterapia y de sus complicaciones (2)

  2009cites this paper
• Advances in the treatment of neutropenia

  2009cites this paper
• Current World Literature

  2009cites this paper